Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes

Authors :: Agostino Cortelezzi
Ivo Nnane
Guillermo Garcia-Manero
Mariëlle Beckers
Vadim A Doronin
Brayan Merchan
María Díez-Campelo
Helen Varsos
Nikki A. Deangelis
Matteo G. Della Porta
Koen Van Eygen
Liang Xiu
Dimitri Breems
Esther Rose
Edo Vellenga
Valle Gomez
Meagan A. Jacoby
Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Stem Cell Aging Leukemia and Lymphoma (SALL)
Source :: American Journal of Hematology, 96(4), E111-E114. Wiley
Publication Year :: 2021

Subjects :: medicine.medical_specialty
business.industry
Internal medicine
Myelodysplastic syndromes
Transfusion dependence
MEDLINE
Medicine
Daratumumab
Hematology
business
medicine.disease

Tools